By Judith Wenshuk, peptide research writer
Quick Answer: Retatrutide is the newest and most powerful compound in the GLP-1 family, activating three receptors (GLP-1, GIP, and glucagon) instead of one or two. Phase 2 trial data showed an average of 24.2% weight loss over 48 weeks at the highest dose, with Phase 3 data pushing that as high as 28.7% — the strongest results of any compound in this category studied so far, available in Canada through research peptide suppliers.
Retatrutide has generated more interest than almost any other research peptide in the last two years, largely because its trial results have consistently outperformed every other compound in the GLP-1 family. Here’s what the actual data shows, and what Canadian researchers are reporting from real-world use.
How It Works
Where Semaglutide activates one receptor (GLP-1) and Tirzepatide activates two (GLP-1 and GIP), Retatrutide is a triple agonist — activating GLP-1, GIP, and glucagon receptors simultaneously. The added glucagon activity is believed to be what pushes its results beyond the other two, since glucagon receptor activity is linked to increased energy expenditure in addition to the appetite effects shared with the other compounds.
Typical Research Protocol
Eli Lilly’s Phase 2 trial used a gradual four-dose escalation:
- Weeks 1–4: 2mg weekly
- Weeks 5–8: 4mg weekly
- Weeks 9–12: 8mg weekly
- Week 13 onward: 12mg weekly (highest studied dose)
As with other compounds in this category, the gradual escalation exists specifically to manage tolerability — jumping straight to a higher dose is associated with substantially more difficult side effects during the first weeks.
What the Data Shows
Phase 2 trial results at the 12mg dose averaged 24.2% weight loss over 48 weeks, with more than 80% of participants losing at least 15% of their starting body weight. Later Phase 3 data (the TRIUMPH trial program) pushed those numbers even further, with results up to 28.7% over a longer duration — alongside a notable secondary finding of liver fat reduction as high as 86% in some measurements, an effect that’s drawn separate research interest on its own.
What Canadian Researchers Report
Self-reported data from research communities tells a slightly different story than the trial numbers, which is worth knowing going in: real-world reports average closer to 15% weight change by month 6 and 18–22% by month 12 — still substantial, but somewhat below the controlled trial environment’s numbers, which is typical when comparing self-reported use to a monitored clinical trial. The most consistently reported side effect during escalation is nausea, and the most common tip shared across research communities is injecting before sleep, which several report makes the nausea considerably easier to manage.
How It Compares
If you’re deciding between Retatrutide and the other GLP-1 compounds, we’ve written full comparisons against both Tirzepatide and against Semaglutide and Tirzepatide together.
Frequently Asked Questions
Is Retatrutide stronger than Tirzepatide? Based on trial data, yes — Retatrutide’s triple-receptor mechanism has produced higher average weight loss than Tirzepatide’s dual-receptor mechanism in comparable trial designs.
Why does Retatrutide reduce liver fat specifically? This isn’t fully settled in the research yet, but it’s believed to relate to the added glucagon receptor activity, which affects metabolic processes beyond appetite alone.
Is Retatrutide available as a research compound in Canada? Yes — Retatrutide is available through research peptide suppliers in Canada, sold strictly for laboratory research.
Leave a Reply